December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

7.210 USD UNCHANGED
Streaming Delayed Price Updated: 7:19 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Immunogen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference
ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting 
From Business Wire News Releases
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia
ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia 
From Business Wire News Releases
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences 
From Business Wire News Releases
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results 
From Business Wire News Releases
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference 
From Business Wire News Releases
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results 
From Business Wire News Releases
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China 
From Business Wire News Releases
ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility
ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility 
From Business Wire News Releases
Thinking about buying stock in ImmunoGen, Lithium Americas Corp, Cytokinetics, Kosmos Energy, or Amarin Corp?
InvestorsObserver issues critical PriceWatch Alerts for IMGN, LAC, CYTK, KOS, and AMRN. 
From PR Newswire
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm 
From Business Wire News Releases
Thinking about buying stock in Vaxart, iBio, ImmunoGen, Adial Pharmaceuticals, or Norwegian Cruise Line?
InvestorsObserver issues critical PriceWatch Alerts for VXRT, IBIO, IMGN, ADIL, and NCLH. 
From PR Newswire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for people with central nervous system (CNS) disorders, today... 
From Business Wire News Releases
ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO 
From Business Wire News Releases
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference 
From Business Wire News Releases
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results 
From Business Wire News Releases
ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference
ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference 
From Business Wire News Releases
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer 
From Business Wire News Releases
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results 
From Business Wire News Releases
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting 
From Business Wire News Releases
ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders
ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders 
From Business Wire News Releases
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer
ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.